Implementation of a comprehensive medication management service for radioiodine therapy patients at an oncology hospital in Rio de Janeiro

Abstract

Introduction

Radioiodine therapy (RIT) can be used in differentiated thyroid carcinoma (DTC), the most frequent type of thyroid cancer in Brazil. It requires continuous preparation and monitoring, which includes management of pharmacotherapy. Evaluating health issues and medications during the pre- and post-RIT period is essential, and comprehensive medication management (CMM) can be a valuable tool.

Objective

This study aimed to describe the implementation of the CMM service for DTC patients and submitted to RIT in a reference oncology hospital in Rio de Janeiro.

Methods

Descriptive implementation study was developed, according to the StaRI statement (Standards for Reporting Implementation Studies), from 03/2020 to 12/2022. Data were collected from the CMM service and the institution's electronic medical record. The service indicators were analyzed through descriptive statistics.

Results

Total of 100 patients were followed, 82.0% being women, with an average age of 47.9 years and an average of 4.76 health problems. Papillary DTC was most frequent (89.0%), at stage I (65.0%), and 49.0% at intermediate risk of recurrence. A total of 140 CMM consultations were held, 72.0% in the pre-RIT period. A total of 118 drug therapy problems (DTP) were identified, 41.5% of which were resolved, and 186 interventions were performed: 114 with the medical team, with acceptability of 33.6%; and 59 interventions with patients, with acceptability of 42.4%.

Conclusion

The study concluded that CMM service should be encouraged for DTC patients undergoing RIT as an effective tool for pharmacotherapy management, particularly in the pre-RIT period.